Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Feb 3;20(4):381–390. doi: 10.1002/clc.4960200416

Long‐term management of atrial fibrillation

A John Camm 1, Mark M Gallagher 1,✉, A John Camm 1
PMCID: PMC6656128  PMID: 9098600

Abstract

In the past decade, catheter ablation techniques and implantable devices have revolutionized the treatment of ventricular arrhythmias, junctional arrhythmias, and atrial flutter. For most patients presenting with atrial fibrillation (AF), the treatment available today is similar to that used a century ago, although nonpharmacologic strategies of therapy have begun to emerge for selected cases. There have been important recent advances in our understanding of the pathophysiology of AF and its complications, and it may be possible to improve patient management by refinement of the way in which current drugs are used.

Keywords: atrial fibrillation, arrhythmia, drug therapy, defibrillator, pacemaker

Full Text

The Full Text of this article is available as a PDF (1.1 MB).

References

  • 1. Coumel P: Neural aspects of paroxysmal atrial fibrillation In Atrial Fibrillation: Mechanisms and Management (Eds. Falk RH, Podrid PJ.), p. 109–125. New York: Raven Press. [Google Scholar]
  • 2. Rasmussen K, Wang H, Fausa D: Comparative efficacy of quinidine and verapamil in the maintenance of sinus rhythm after DC cardioversion of atrial fibrillation. A controlled clinical trial. Acta Med Stand 1981; (suppl 645): 23–28. [DOI] [PubMed] [Google Scholar]
  • 3. Szekely P, Sideris DA, Batson GA: Maintenance of sinus rhythm after atrial fibrillation. Br Heart J 1970; 32: 741–746. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Boissel JP, Wolf E, Gillet J, Soubrane A, Cavallaro A, Mozoyer G: Controlled trial of a long acting quinidine for maintenance of sinus rhythm after conversion of sustained atrial fibrillation. Eur Heart J 1981; 2: 49–55. [DOI] [PubMed] [Google Scholar]
  • 5. Karlson BW, Torstensson I, Abjorn C, Yansson GO, Peterson LE: Disopyramide in the maintenance of sinus rhythm after electroversion of atrial fibrillation—a placebo controlled one year followup study. Eur Heart J 1988; 9: 284–290. [DOI] [PubMed] [Google Scholar]
  • 6. Pritchett ELC, McCarthy EA, Wilkinson WE: Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias: A randomised, placebo controlled, crossover trial in patients tolerating oral therapy. Ann Intern Med 1991; 114: 539–544. [DOI] [PubMed] [Google Scholar]
  • 7. Anderson JL, Gilbert EM, Alpert BL, Henthorn RW, Waldo AL, Bhandari AK, Hawkinson RW, Pritchett ELC: Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy: A multicenter, double‐blind, crossover study of flecainide and placebo with transtelephonic monitoring: Flecainide Supraventricular Tachycardia Study Group. Circulation 1989; 80: 1557–1570. [DOI] [PubMed] [Google Scholar]
  • 8. Graboys TB, Podrid PJ, Lown B: Efficacy of amiodarone for refractory supraventricular arrhythmias. Am Heart J 1983; 106: 870–876. [DOI] [PubMed] [Google Scholar]
  • 9. Jull‐Moller S, Edvardsson N, Rehnqvist‐Ahlberg N: Sotalol versus quinidine for the maintenance of sinus rhythm after the direct current cardioversion of atrial fibrillation. Circulation 1990; 82: 1932–1939. [DOI] [PubMed] [Google Scholar]
  • 10. Cox JL, Schuessler RB, D'Agostino HJ, Stone CM, Chang BC, Cain ME, Corr PB, Boineau JP: The surgical treatment of atrial fibrillation III. Development of a definitive surgical procedure. J Thorac Cardiovasc Surg 1991; 101: 569–583. [PubMed] [Google Scholar]
  • 11. Murgatroyd FD, Camm AJ: Maintenance of sinus rhythm in patients at risk of atrial fibrillation In Atrial Arrhythmias: State of the Art (Eds. DiMarco JP, Prystowsky EN.). Armonk: Futura, 1995. [Google Scholar]
  • 12. Van Gelder IC, Tieleman RG, Brugemann J, Gosselink MAT, Crijns HJ: Chronic atrial fibrillation: Success rate of serial cardioversion therapy and long term safety of oral anticoagulant therapy (abstr). Circulation 1996; 94 (suppl 1): I–70. [Google Scholar]
  • 13. Grogan M, Smith HC, Gersh BJ, Wood DL: Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992; 69: 1570–1573. [DOI] [PubMed] [Google Scholar]
  • 14. Peters KG, Kienzle MG: Severe cardiomyopathy due to chronic rapidly conducted atrial fibrillation: Complete recovery after restoration of sinus rhythm. Am J Med 1988; 85: 242–244. [DOI] [PubMed] [Google Scholar]
  • 15. Van Gelder IC, Crijns HJGM, Blanksma PK, Landsman MLJ, Posma JL, Van Den Berg MP, Meijler FL, Lie KI: Time course of hemodynamic changes and improvement of exercise tolerance after cardioversion of chronic atrial fibrillation unassociated with cardiac valve disease. Am J Cardiol 1993; 72: 560–566. [DOI] [PubMed] [Google Scholar]
  • 16. Edner M, Caidahl K, Bergfeldt L, Darpo B, Edvardsson N, Rosenqvist M: Prospective study of left ventricular function after radiofrequency ablation of atrioventricular junction in patients with atrial fibrillation. Br Heart J 1995; 74: 261–267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Blumgart H: The reaction to exercise of the heart affected by auricular fibrillation. Heart 1924; 11: 49–55. [Google Scholar]
  • 18. Redfors A: The effect of different digoxin doses on subjective symptoms and physical working capacity in patients with atrial fibrillation. Acta Med Scand 1971; 190: 307–320. [DOI] [PubMed] [Google Scholar]
  • 19. Redfors A: Digoxin dosage and ventricular rate at rest and exercise in patients with atrial fibrillation. Acta Med Scand 1971; 190: 321–333. [DOI] [PubMed] [Google Scholar]
  • 20. Lang R, Klein HO, Di Segni E, Gefen J, Sareli P, Libhaber C, David D, Weiss E, Guerrero J, Kaplinsky E: Verapamil improves exercise capacity in chronic atrial fibrillation: Double‐blind crossover trial. Am Heart J 1983; 105: 820–825. [DOI] [PubMed] [Google Scholar]
  • 21. Lang R, Klein HO, Weiss E, David D, Sareli P, Levy A, Guerrero J, Di Segni E, Kaplinsky E: Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation. Chest 1983; 83 (3): 491–499. [DOI] [PubMed] [Google Scholar]
  • 22. Lewis R, Lakhani M, Moreland TA, McDevitt DG: A comparison of verapamil and digoxin in the treatment of atrial fibrillation. Eur Heart J 1987; 8: 148–153. [DOI] [PubMed] [Google Scholar]
  • 23. Lewis RV, Laing E, Moreland TA, Service E, McDevitt DG: A comparison of digoxin, diltiazem and their combination in the treatment of atrial fibrillation. Eur Heart J 1988; 9: 279–283. [DOI] [PubMed] [Google Scholar]
  • 24. Lewis RV, Irvine N, McDevitt DG: Relationships between heart rate, exercise tolerance and cardiac output in atrial fibrillation: The effects of treatment with digoxin, verapamil and diltiazem. Eur Heart J 1988; 9: 777–781. [DOI] [PubMed] [Google Scholar]
  • 25. Matsuda M, Matsuda Y, Yamagashi T, Takahashi T, Haraguchi M, Tada T, Kusukawa R: Effects of digoxin, propranolol and verapamil on exercise in patients with chronic isolated atrial fibrillation. Cardiovasc Res 1991; 25: 453–457. [DOI] [PubMed] [Google Scholar]
  • 26. Lundstrom T, Ryden L: Ventricular rate control and exercise performance in chronic atrial fibrillation: Effects of diltiazem and verapamil. J Am Coll Cardiol 1990; 16: 86–90. [DOI] [PubMed] [Google Scholar]
  • 27. Channer KS, Papouchado M, James MA, Pitcher DW, Rees JR: Towards improved control of atrial fibrillation. Eur Heart J 1987; 8: 141–147. [DOI] [PubMed] [Google Scholar]
  • 28. Koh KK, Kwon KS, Park HB, Baik SH, Park SJ, Lee KH, Kim EJ, Kim SH, Cho SK, Kim SS: Efficacy and safety of digoxin alone and in combination with low‐dose diltiazem or betaxolol to control ventricular rate in chronic atrial fibrillation. Am J Cardiol 1995; 75 (1): 88–90. [DOI] [PubMed] [Google Scholar]
  • 29. Reiffel JA: Improved rate control in atrial fibrillation. Am Heart J 1992; 123 (4): 1094–1098. [DOI] [PubMed] [Google Scholar]
  • 30. Lundstrom T, Moor E, Ryden L: Differential effects of xamoterol and verapamil on ventricular rate regulation in patients with chronic atrial fibrillation. Am Heart J 1992; 124 (4): 917–923. [DOI] [PubMed] [Google Scholar]
  • 31. James MA, Channer KS, Papouchado M, Rees JR: Improved control of atrial fibrillation with combined pindolol and digoxin therapy. Eur Heart J 1989; 10: 83–90. [DOI] [PubMed] [Google Scholar]
  • 32. Ang EL, Chan WL, Cleland JGF, Moore D, Krikler SJ, Alexander NDE, Oakley CM: Placebo controlled trial of xamoterol versus digoxin in chronic atrial fibrillation. Br Heart J 1990; 64: 256–260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Brodsky M, Saini R, Bellinger R, Zoble R, Weiss R, Powers L: Comparative effects of the combination of digoxin and dl‐sotalol therapy versus digoxin monotherapy for control of ventricular response in chronic atrial fibrillation, dl‐Sotalol Atrial Fibrillation Study Group. Am Heart J 1994; 127 (3): 572–577. [DOI] [PubMed] [Google Scholar]
  • 34. Atwood JE, Sullivan M, Forbes S, Myers J, Pewen W, Olson HG, Froelicher VF: Effect of beta‐adrenergic blockade on exercise performance in patients with chronic atrial fibrillation. J Am Coll Cardiol 1987; 10 (2): 314–320. [DOI] [PubMed] [Google Scholar]
  • 35. DiBianco R, Morganroth J, Freitag JA, Ronan JA, Lindgren KM, Donohue DJ, Larca LJ, Chadda KD, Olukotum AY: Effects of nadolol on the spontaneous and exercise‐provoked heart rate of patients with chronic atrial fibrillation receiving stable dosages of digoxin. Am Heart J 1984; 108: 1121–1127. [DOI] [PubMed] [Google Scholar]
  • 36. Prytowsky EN, Benson DW, Fuster V, Hart RG, Kay GN, Myerburg RJ, Naccarelli GV, Wyse G: Management of patients with atrial fibrillation. A statement for healthcare professionals from the committee on electrocardiography and electrophysiology, American Heart Association. Circulation 1996; 93: 1262–1277. [DOI] [PubMed] [Google Scholar]
  • 37. Redfield MM, Kay GN, Martin RC, Jensen DN, Newhouse TT: Tachycardia related cardiomyopathy—a common and reversible cause of ventricular dysfunction in patients with atrial fibrillation (abstr). Circulation 1996; 94 (suppl 1): I–21. [Google Scholar]
  • 38. Ellenbogen KA, Kay GN, Guidici M, Redfield MM, Jenkins L, Takle‐Newhouse T, Jensen DN, Martin R, the APT Trial Investigators : Radiofrequency ablation of the AV junction improves functional status in patients with congestive heart failure: Results from the APT trial (abstr). Circulation 1996; 94 (suppl 1): I–682. [Google Scholar]
  • 39. Kay GN, Ellenbogen KA, Guidici M, Martin R, Jensen DN, Jenkins L, Takle‐Newhouse T: Survival in the APT trial: A prospective registry of AV node ablation and permanent pacemaker implantation for symptomatic atrial fibrillation (abstr). Circulation 1996; 94 (suppl 1): I–682. [Google Scholar]
  • 40. Gardner MJ, Gilbert M: Heart rate control in patients with atrial fibrillation. Can J Cardiol 1996; 12 (suppl A): 21A–23A. [PubMed] [Google Scholar]
  • 41. Menozzi C, Brignole M, Gianfranchi L, Lolli G, Oddone D, Gaggioli G, Bottoni N: Radiofrequency catheter ablation and modulation of atrioventricular conduction in patients with atrial fibrillation. PACE 1994; 17 (2): 2143–2149. [DOI] [PubMed] [Google Scholar]
  • 42. Feld GK, Fleck RP, Fujimura O, Prothro DL, Bahnson TD, Ibarra M: Control of rapid ventricular response by radiofrequency catheter modification of the atrioventricular node in patients with medically refractory atrial fibrillation. Circulation 1994; 90: 2299–2307. [DOI] [PubMed] [Google Scholar]
  • 43. Williamson BD, Ching‐Man K, Daoud E, Niebauer M, Strickberger A, Morady F: Radiofrequency catheter modification of atrioventricular conduction to control the ventricular rate during atrial fibrillation. N Engl J Med 1994; 331: 910–917. [DOI] [PubMed] [Google Scholar]
  • 44. Ezekowitz MD, James KE, Nazarian SM, Davenport J, Broderick JP, Gupta SR, Thadani V, Meyer ML, Bridgers SL: Silent cerebral infarction in patients with nonrheumatic atrial fibrillation. The Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Circulation 1995; 92 (8): 2178–2182. [DOI] [PubMed] [Google Scholar]
  • 45. Stotard MF, Dawkins PR, Prince CM, Ammash NM: Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: A transesophageal echocardiographic study. J Am Coll Cardiol 1995; 25 (2): 452–459. [DOI] [PubMed] [Google Scholar]
  • 46. Petersen P, Boysen G, Godtfredsen J, Andersen CD, Andersen B: Placebo‐controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenhagen AFASA K study. Lancet 1989; 1: 175–178. [DOI] [PubMed] [Google Scholar]
  • 47. The Boston area anticoagulation trial for atrial fibrillation investigators : The effect of low dose warfarin on the risk of stroke in patients with non‐rheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505–1511. [DOI] [PubMed] [Google Scholar]
  • 48. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, Krause‐Steinrauf H, Kurtzke JF, Nazarian SM, Radford MJ, Rickles FR, Shabetai R, Deykin D, for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators : The veterans affairs stoke prevention in nonrheumatic atrial fibrillation investigators: Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992; 327: 1406–1412. [DOI] [PubMed] [Google Scholar]
  • 49. The Stroke Prevention in Atrial Fibrillation Study Group Investigators : Stroke prevention in atrial fibrillation study: Final results. Circulation 1991; 84: 527–539. [DOI] [PubMed] [Google Scholar]
  • 50. Stroke Prevention in Atrial Fibrillation Investigators : Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke prevention in atria! fibrillation 11 study. Lancet 1994; 343: 687–691. [PubMed] [Google Scholar]
  • 51. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C: Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol 1991; 18: 349–355. [DOI] [PubMed] [Google Scholar]
  • 52. European Atrial Fibrillation Trial Study Group : Secondary prevention in non‐rheumatic atrial fibrillation after ischaemic attack or major stroke. Lancet 1993; 342: 1255–1262. [PubMed] [Google Scholar]
  • 53. Atrial Fibrillation Investigators : Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomised controlled trials. Arch Intern Med 1994; 154; 1449–1457. [PubMed] [Google Scholar]
  • 54. Wolf PA, Dawber TR, Thomas HE, Kannel WB: Epidemiological assessment of chronic atrial fibrillation and risk of stroke: The Framingham study. Neurology 1978; 28: 973–977. [DOI] [PubMed] [Google Scholar]
  • 55. Caplan LR, D'Cruz I, Hier DB, Reddy H, Shah S: Atrial size, atrial fibrillation, and stroke. Ann Neurol 1986; 19: 158–161. [DOI] [PubMed] [Google Scholar]
  • 56. Cabin HS, Clubb S, Hall C, Perlmutter RA, Feinstein AR: Risk for systemic embolization of atrial fibrillation without mitral stenosis. Am J Cardiol 1990; 65: 1112–1116. [DOI] [PubMed] [Google Scholar]
  • 57. Kopecky SL, Gersh BJ, McGoon MD, Whisnant JP, Holmes DR, Ilstrup DM, Frye RL: The natural history of lone atrial fibrillation: A population‐based study over three decades. N Engl J Med 1987; 317: 669–674. [DOI] [PubMed] [Google Scholar]
  • 58. Kannel WB, Abbott RD, Savage DD, McNamara PM: Epidemiological features of chronic atrial fibrillation: The Framingham study. N Engl J Med 1982; 306: 1018–1022. [DOI] [PubMed] [Google Scholar]
  • 59. Selzer A: Atrial fibrillation revisited. N Engl J Med 1982; 306: 1044–1045. [DOI] [PubMed] [Google Scholar]
  • 60. Petersen P, Godtfredsen J: Embolic complications in paroxysmal atrial fibrillation. Stroke 1986; 17: 622–626. [DOI] [PubMed] [Google Scholar]
  • 61. The Stroke Prevention in Atrial Fibrillation Investigators : Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 1996; 156 (4): 409–416. [PubMed] [Google Scholar]
  • 62. The European Atrial Fibrillation Trial Study Group : Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia (see comments). N Engl J Med 1995; 333 (1): 5–10. [DOI] [PubMed] [Google Scholar]
  • 63. Hylek EM, Skates SJ, Sheehan MA, Singer DE: An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996; 335: 540–546. [DOI] [PubMed] [Google Scholar]
  • 64. Cowburn P, Cleland JGF: Clinical trial update: SPAF‐III results (letter). Eur Heart J 1996; 17: 1129. [DOI] [PubMed] [Google Scholar]
  • 65. Connolly SJ, Turpie AGG: Antithrombotic therapy in atrial fibrillation. Can J Cardiol 1996; 12 (suppl A): 17A–20A. [PubMed] [Google Scholar]
  • 66. Swartz JF, Pellerseis G, Silvers J, Patten L, Cervantez D: A catheter‐based approach to atrial fibrillation in humans (abstr). Circulation 1994; I–335.
  • 67. Swartz J: Can we reproduce the MAZE procedure by RF catheter ablation? Paper presented at “Nonpharmacological Management of Atrial Fibrillation.” 1996; April 11–12; London.
  • 68. Elvan A, Pride HP, Eble JN, Zipes D: Radiofrequency catheter ablation of the atria reduces inducibility and duration of atrial fibrillation in dogs. Circulation 1995; 91: 2235–2244. [DOI] [PubMed] [Google Scholar]
  • 69. Fuer JM, Shandling AH, Messenger JC: Influence of cardiac pacing mode on the long term development of atrial fibrillation. Am J Cardiol 1989; 64: 1376–1379. [DOI] [PubMed] [Google Scholar]
  • 70. Coumel P, Friocourt P, Mugica J, Attuel P, Leclercq JF: Long term prevention of vagal arrhythmias by atrial pacing at 90/min. Experience with 6 cases. PACE 1983; 6: 522–560. [DOI] [PubMed] [Google Scholar]
  • 71. Daubert C, Mabo P, Berder V, Le Breton H, Leclercq C, Gras D: Permanent dual atrium pacing in major interatrial conduction blocks: A four year experience (abstr). PACE 1993; 16: 885. [Google Scholar]
  • 72. Murgatroyd FD, Nitzsche R, Slade AKB, Limousin M, Rossel N, Camm AJ, Ritter P: A new algorithm for overdrive suppression of atrial fibrillation. PACE 1994; 17 (2): 1966–1973. [DOI] [PubMed] [Google Scholar]
  • 73. Murgatroyd FD, Slade AK, Sopher SM, Rowland E, Ward DE, Camm AJ: Efficacy and tolerability of transvenous low energy cardioversion of paroxysmal atrial fibrillation in humans. J Am Coll Cardiol 1995; 25 (6): 1347–1353. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES